
Sign up to save your podcasts
Or


Texas Medical Center CEO William McKeon wants Texas to serve as the U.S. pilot for faster, cheaper clinical trials. In an interview with BioCentury Editor in Chief Simone Fishburn on The BioCentury Show, McKeon described how TMC’s centralized IRB gives sponsors a single approval covering 10 million patients, and his push to extend it statewide. He also discussed competition from China, Australia and Spain for early-stage trials and a proposed Australia-style refundable R&D tax credit for the upcoming Texas legislative session. This episode of The BioCentury Show has been brought to you by Tigermed.
View full story: https://www.biocentury.com/article/661560
#ClinicalTrials #LifeSciences #HealthPolicy #Texas #ClinicalResearch
0:00 Introduction
01:15 TMC in a Nutshell
11:57 A Model for the U.S.
15:23 Competing with China
18:46 Policy Proposals: Tax Credit
27:47 Embedding Trials in Care
On this edition of The BioCentury Show, Gilde's Joep Muijrers joins BioCentury’s Stephen Hansen to discuss how the firm’s Impact Council of former regulators, payers, HTA leaders, and patient advocates shapes its investment decisions. Muijrers explains how council input steered Gilde away from one deal and toward another, diagnostics company Karius, and why he argues patient perspectives belong alongside physician input in diligence and development strategy. He also describes the frameworks Gilde has developed for engaging patient organizations, and why he urges other investors to adopt them as a pre-competitive practice. This episode of The BioCentury Show is brought to you by Tigermed.
View full story: https://www.biocentury.com/article/661356
#PatientEngagement #BiotechInvesting #ImpactInvesting #VentureCapital #MarketAccess
0:00 Introduction
2:00 Creating Gilde's Impact Council
7:32 Advisors' Impact on Investing
16:42 Gilde's Approach to Patient Engagement
23:50 Where Patient Input Fits in Decision-making
29:17 Why Other Investors Should Engage
Tigermed, the largest clinical CRO in China, has expanded into more than 50 countries and is growing its North American operations, offering full-service support from preclinical through Phase IV. On this sponsored edition of The BioCentury Show, Britney Winterberger, Tigermed’s VP and head of North America clinical operations, tells BioCentury Executive Editor Jeff Cranmer how the CRO helps U.S. sponsors run trials in China and Chinese sponsors run trials in the U.S. — and why combining both in a single protocol can de-risk FDA acceptance while capturing China’s enrollment speed. Winterberger also discusses investigator-initiated trials in China, China’s new IIT regulations, and trial trends spanning bispecifics, ADCs, cell and gene therapies, and radiopharmaceuticals.
This episode of The BioCentury Show is brought to you by Tigermed.
View full story: https://www.biocentury.com/article/661260
#GlobalClinicalTrials #IITs #Oncology #ADCs #CRO
0:00 Introduction
1:17 Tigermed's Global Capabilities
2:59 Running Trials in China
7:05 Chinese Sponsors in the U.S.
16:42 IITs
22:28 Trends in Trial Design
Arrowhead Pharmaceuticals can now deliver siRNA to seven cell types, and new data showing subcutaneous delivery to the brain could push RNAi therapies well beyond the liver. On this edition of The BioCentury Show, Arrowhead Chairman, President, and CEO Chris Anzalone joins BioCentury’s Stephen Hansen to discuss where siRNA has the edge over ASOs, what the Phase III miss for Novartis’ pelacarsen means for olpasiran, the Lp(a) therapy Arrowhead partnered with Amgen, and the growth outlook for plozasiran in severe hypertriglyceridemia. Anzalone also describes Arrowhead’s obesity programs targeting INHBE and ALK7, and a dimer molecule that silences two genes at once.
View full story: https://www.biocentury.com/article/661194
#RNAi #siRNA #DrugDelivery #DrugDevelopment #Biotech
0:00 Introduction
1:09 Arrowhead's siRNA Platform
9:05 Solving for Extra-Hepatic Delivery
23:43 Redemplo's Future Growth
27:00 Obesity and Bispecific siRNA
Untapped multibillion-dollar markets are hiding in plain sight where patients endure mediocre generic standards of care, according to Canaan General Partner Julie Grant, co-founder and first CEO of Day One, which Servier acquired for $2.5 billion this year. In an interview with BioCentury's Lindsay Martin, Grant discussed white spaces in women's health such as migraine and anemia, and why mid-tier acquirers like Jazz, Ipsen and Servier make smaller markets viable. She also explained why the last private round can understate value by 10-20X, how Canaan builds management teams around a key individual who sets the tone and why biotech needs scientific heroes as AI captures most venture dollars.
View full story: https://www.biocentury.com/article/660963
#VentureCapital #Biotech #WomensHealth #DrugDevelopment #BiotechMA
0:00 Introduction
1:19 Canaan's Strategy
11:34 Team Building
21:57 White Space
28:00 New Biotech Buyers
34:15 Biotech Founders
On this edition of The BioCentury Show, Nick Galakatos, Global Head of Life Sciences at Blackstone, joins Editor in Chief Simone Fishburn to discuss the path from Clarus to Blackstone's new $6.3 billion fund, and the goal of game-changing bets.
Galakatos discusses Blackstone's thesis for addressing the late-stage financing gap, as Phase III programs costing more than $1 billion drive demand for large, product-based capital. He also addresses structured capital as an alternative to acquisition, noting deals such as Blackstone's with Alnylam and Apogee can reduce dilution and extend runway.
View full story: https://www.biocentury.com/article/660824
#Biotech #PrivateEquity #DrugDevelopment #LifeSciences #ClinicalTrials
0:00 Introduction
1:22 New Fund & Founding
10:30 Alnylam Deal
17:14 Working with Big Caps
25:54 Biotech Risk
29:13 China
On This Edition of The BioCentury Show, Gonçalo Abecasis, SVP and Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center, joins BioCentury’s Tierney Baum to discuss genetics as a scalable drug discovery platform and the practical use of AI in genomics.
View full story: https://www.biocentury.com/article/660697
#Genomics #DrugDiscovery #AI #GeneticMedicines #ClinicalTrials
0:00 - Introduction
1:14 - Regeneron Genetics Center
10:29 - Acting on Genetic Signals
16:57 - Getting to Drug Development
21:51 - Best AI Use Cases
The Critical Path Institute’s One to Millions Initiative is using individualized rare disease therapies as the starting point for a development framework that could eventually extend across all genetically defined diseases. The initiative seeks to bring form to FDA’s Plausible Mechanism Framework by standardizing how evidence and methods can be reused across therapies and patients.
In conversation with Biopharma Analyst Dr. Tierney Baum on The BioCentury Show, C-Path CEO and CSO Klaus Romero discusses how the principal bottleneck is no longer the ability to design therapies for individual patients but rather the absence of a standardized regulatory and development system that can translate one success into many. C-Path plans to bring companies, academics, patient groups, and regulators together to share data and address recurring development bottlenecks.
View full story: https://www.biocentury.com/article/660583
#GeneticMedicines #RareDisease #DrugDevelopment #RegulatoryScience #ClinicalTrials
00:00 - Introduction
01:44 - Current Framework
07:01 - Process-based Regulation
13:57 - Overcoming Bottlenecks
20:28 - Use of AI
25:25 - Beyond Rare Diseases
Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy Levin has challenged the industry to live up to its ideals. In an interview with BioCentury Washington Editor Steve Usdin, Levin discussed why he believes industry leaders should speak out, and why many remain silent, about critical issues. He described concerns about the strength of the pillars that support the U.S. biotech industry, and why he is optimistic about the future of biotech.
View full story: https://www.biocentury.com/article/660408
#Biotech #DrugPricing #BiopharmaPolicy #ChinaBiotech #Innovation
00:00 - Introduction
03:24 - Biotech Under Threat
10:38 - CEO Compensation
15:39 - Competing with China
22:08 - U.S. Policy Prescriptions
30:00 - Looking Ahead
As AI becomes increasingly commoditized, Initiate Ventures' Jessica Owens argues healthcare and life sciences companies need to use it to solve historically intractable problems, not just streamline workflows. On The BioCentury Show, Owens breaks down how she evaluates founders, when Initiate chooses to fund versus co-found a company, and why she believes proprietary data now matters more than any proprietary model.
Owens also discusses gaps in evidence generation for diagnostics, and closes with a look at MASH, arguing that better non-invasive fibrosis staging will become increasingly critical as more GLP-1 combination therapies reach patients.
View full story: https://www.biocentury.com/article/660203
#AI #VentureCapital #Diagnostics #HealthTech #DrugDevelopment
00:00 - Introduction
01:15 - Initiate Ventures' Thesis
07:04 - What Makes Founders Fundable
17:36 - Defining AI Native Healthcare
23:20 - Diagnostics & Evidence Generation
36:44 - Non-Invasive Fibrosis Testing
From the publisher's feed
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.
Join our Senior Editors in face-to-face discussions with scientific KOLs,…
The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.
Don't miss this event, every two weeks, now available as a video webcast or audio podcast.

965 Listeners

2,322 Listeners

124 Listeners

338 Listeners

6,066 Listeners

62 Listeners

10,167 Listeners

33 Listeners

549 Listeners

5,588 Listeners

20 Listeners

293 Listeners

14 Listeners

1,445 Listeners

62 Listeners